Urinary F-2-Isoprostanes as a Biomarker of Reduced Risk of Type 2 Diabetes

作者：Il' yasova Dora; Spasojevic Ivan; Base Karel; Zhang Haoyue; Wang Frances; Young Sarah P; Millington David S; D' Agostino Ralph B Jr; Wagenknecht Lynne E

来源：Diabetes Care, 2012, 35(1): 173-174.

DOI：10.2337/dc11-1502

OBJECTIVE We have previously reported evidence of an inverse association between a urinary F-2-isoprostane and type 2 diabetes risk in a pilot case-control study nested within the Insulin Resistance Atherosclerosis Study (IRAS). Here, we report the results from the study extended to the entire IRAS cohort. %26lt;br%26gt;RESEARCH DESIGN AND METHODS This prospective study included 138 incident type 2 diabetes case and 714 noncase subjects. Four F-2-isoprostanes (iPF2 alpha.-III; 2,3-dinor-iPF2 alpha-III; iPF2 alpha-VI; and 8,12-iso-iPF2 alpha-VI) were assayed in baseline urine samples using liquid chromatography tandem mass spectrometry. %26lt;br%26gt;RESULTS Three F2-isoprostanes showed significant inverse associations with type 2 diabetes risk: the adjusted odds ratios were 0.52 (95% Cl 0.39-0.67), 0.56 (0.42-0.73), 0.62 (0.48-079), and 0.91 (0.72-1.12) for iPF2 alpha-III, 2,3-dinor-iPF2 alpha-III; iPF2 alpha-VI; and 8,12-iso-iPF2 alpha-VI, respectively. %26lt;br%26gt;CONCLUSIONS Our findings indicate that urinary F-2-isoprostanes are inversely associated with type 2 diabetes risk beyond the traditional risk factors and may be useful in identifying highrisk populations.

• 出版日期2012-1